ReviewCancers2026
Megakaryocyte-Platelet Immunometabolism in Leukemic Niche Remodeling.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Megakaryocytes (MKs) and platelets are increasingly recognized as active regulators of the bone marrow (BM) microenvironment rather than passive effectors of thrombopoiesis and hemostasis. Recent single-cell and lineage-tracing studies have established that megakaryopoiesis generates functionally heterogeneous populations, including immune-biased and niche-supporting subsets that shape hematopoietic stem cell (HSC) behavior, inflammatory tone, and vascular homeostasis. In leukemia, these regulatory circuits are systematically rewired to establish a marrow niche that suppresses normal hematopoiesis while sustaining leukemic stem cell (LSC) fitness through cytokine gradients, stromal remodeling, and direct cell-to-cell communication. In this focused review, we propose that the immune MK (iMK)-platelet axis is a central driver of leukemic niche remodeling. We discuss how iMK states arise under leukemic pressure, how MK heterogeneity encodes distinct niche instructions, and how platelet-derived extracellular vesicles (EVs) distribute inflammatory signals across the marrow and systemic circulation. Within this framework, we position mitochondrial stress outputs-such as reactive oxygen species (mtROS), mitochondrial DNA (mtDNA) release, metabolic rewiring, and mitochondria-containing EV secretion-not as isolated phenomena, but as mechanistic amplifiers embedded within the broader inflammatory and niche-regulatory programs of MKs and platelets. We further highlight preleukemic inflammatory states as an underappreciated entry point for therapeutic intervention, and propose three clinically actionable axes: inflammatory niche interruption, mitochondrial stress modulation, and platelet-leukemia communication blockade. This framework aligns with emerging concepts in MK heterogeneity, innate immune sensing, endothelial remodeling, and preleukemic signaling, and positions the MK-platelet axis as a promising therapeutic framework in leukemia-associated niche remodeling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.